Developer docs
API playgroundTry for free, no card

Search company profiles

Sincrolab

Full company profile

uuid0002vh1

Namestring
Sincrolab
Legal namestring
SINCROLAB S.L.
Websiteurl
sincrolab.es
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Sincrolab S.L. is a Spanish digital therapeutics company, founded in 2013 and headquartered in Madrid (with a registered office in Málaga), that develops AI-powered cognitive therapy software for ADHD and related cognitive disorders. Its core product, the KAD_SCL_01 cognitive stimulation program, deploys 14 adaptive cognitive tasks (including go/no-go and n-back paradigms) through the gamified 'Sea of Heroes' mobile application, with an AI engine that automatically adjusts task content and difficulty in real time based on each patient's daily performance. A separate professional platform allows therapists, clinics, and hospitals to prescribe treatment, monitor compliance, and generate automated progress reports, while families access the program through the Sincroclinic online booking and subscription flow.

Sincrolab holds CE Class IIa certification under EU Medical Device Regulation 2017/745 as the first Spanish company to secure this designation for an AI-based digital ADHD therapy, alongside ISO 13485:2016 (medical device quality) and ISO/IEC 27001:2022 (information security) certifications. Clinical validation rests on three peer-reviewed randomized controlled trials published in the Journal of Medical Internet Research (2021), Brain Communications (2022), and npj Mental Health Research/Nature (2025), with the most recent study reporting 28% of treated children reaching normative range on CPT-C versus 0% in controls and MEG-verified changes in brain activity.

The company monetizes through a €99/month B2C subscription sold directly to families via sincrolab.es, complemented by B2B subscriptions for healthcare professionals and partnerships with clinics, hospitals, and insurers (notably DKV), reaching a reported network of 800+ therapists and 100+ specialized centers across Spain with 6,000+ patients treated to date. Sincrolab has raised approximately €2 million cumulatively across rounds including Wayra (2015, 2018), a €1.7 million round led by Clave Innohealth in June 2024, and a 2026 Eoniq.fund follow-on at an €8.5 million pre-money valuation, with stated priorities of international expansion and new product launches in 2025.

Short descriptiontext

Sincrolab is a Spanish digital therapeutics company that delivers CE-marked, AI-adaptive cognitive therapy for ADHD through its gamified 'Sea of Heroes' platform, sold via €99/month subscriptions to families and through professional licenses to clinicians, clinics, and hospitals across Spain.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMálaga, Spain
HQ citystring
Málaga
HQ countrystring
Spain
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital cognitive therapy, ADHD treatment platform, AI cognitive stimulation, pediatric mental health, gamified neurotherapy
Industry3 codes
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLALABAK
Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)
NAICS code1 code
  • Outpatient Mental Health and Substance Abuse Centers621420
SIC code2 codes
  • Services-Prepackaged Software7372
  • Services-Misc Health & Allied Services, Nec8090
Product category
Digital Therapeutics for ADHD
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Suscripción Mensual Sincrolab (B2C)
TypeSubscription Recurring
Description

Monthly subscription model at €99/month for families, automatically renewed. Includes initial clinical assessment, personalized treatment plan, daily cognitive training activities via Sea of Heroes app, and ongoing professional supervision throughout the treatment cycle.

sincrolab.es
2B2B Platform Licensing / Professional Subscriptions
TypeSubscription Recurring
Description

Sincrolab provides its professional platform to therapists, clinics, and hospitals who prescribe and monitor patient treatment. The platform allows professionals to customize treatment plans, supervise progress remotely, and generate automated reports for their patient base.

sincrolab.es
3Partnerships with Medical and Pharmaceutical Entities
TypeLicensing Royalties
Description

Sincrolab is pursuing partnerships with medical and pharmaceutical entities as part of its expansion strategy, as stated in the Eoniq.fund investment announcement.

webcapitalriesgo.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details2 tiers
1Monthly subscription at €99 per month
ModelSubscriptionBilling cadenceMonthly
Notes

Suscripción Mensual Sincrolab priced at €99.00 EUR per month. Automatically renewed. Includes evaluation, personalized plan, daily activities, and professional supervision. No annual discount or free trial is publicly disclosed.

sincrolab.es
2Initial clinical assessment session (paid administrative fee)
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

The first online appointment for individual case evaluation incurs a clinical management fee to guarantee thorough attention and specialist scheduling.

sincrolab.es
GTM typeB2B and B2C
B2B and B2C
Offering typeSoftware
Software
Brand1 record
1Sea of Heroes
Description

A digital experience designed to accompany daily life with personalized activities, more motivation, and professional follow-up. A serious game with 14 cognitive tasks including go/no-go and n-back exercises that automatically adjust content and difficulty based on performance.

sincrolab.es
Core offering1 text field

Sincrolab provides an AI-powered digital therapeutic platform for cognitive stimulation in children (and adults) with ADHD and attention difficulties. Its flagship product, the KAD_SCL_01 program, is delivered through the gamified 'Sea of Heroes' mobile app and comprises 14 adaptive cognitive tasks (go/no-go, n-back, etc.) that auto-adjust to patient performance, with online clinical assessment, monthly subscription pricing (€99/month), and ongoing professional supervision. A separate professional platform allows therapists, clinics, and hospitals to prescribe, monitor, and report on patient progress remotely.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 28% of the experimental group reached normative range on CPT-C (7/25 participants) vs 0% in control group (p=0.009), as demonstrated in the Nature npj Mental Health Research 2025 RCT
+5 more records
Product overview1 text field

Sincrolab is a digital therapeutics company offering a unified platform combining AI-powered cognitive therapy (KAD_SCL_01) for ADHD and cognitive disorders. The core offering consists of the Sincrolab Platform for patients and professionals, the Sea of Heroes gamified therapy experience, and the Sincroclinic scheduling service. The platform is validated by clinical trials published in peer-reviewed journals including JMIR, Brain Communications, and Nature npj Mental Health Research, and holds CE Class IIa certification as a medical device for ADHD treatment. Pricing is via €99/month subscription through Sincroclinic.

Product and service5 records
1Sincrolab Platform
CategoryDigital Therapeutics Platform
2Sea of Heroes
CategoryGamified Cognitive Training App
3Sincrolab Therapist Platform
CategoryProfessional Clinical Platform
4Sincroclinic
CategoryOnline Booking and Subscription Service
5KAD_SCL_01 Cognitive Stimulation Program
CategoryAI Cognitive Stimulation Engine
Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMinorTypeGTM or Marketing Partner
Description

DKV, a health insurance company, has a partnership or collaboration with Sincrolab. The DKV logo appears in the collaborators section on Sincrolab's professional platform page alongside Wayra, CTB, ELMA, Laboratorios Rubio, and IBM.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Wayra (Telefónica's tech venture capital / accelerator arm) appears in the collaborators section of Sincrolab's professional platform. The connection likely relates to Sincrolab's prior acceleration by Telefónica.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

CTB (Centro de Tecnología Biomédica of Universidad Politécnica de Madrid) appears in the collaborators section. Fernando Maestú PhD, Director of the Cognitive Neuroscience and Computacional Lab at CTB, UPM, and UCM, serves on Sincrolab's Scientific Advisory Board, indicating a research collaboration.

Strategic tierMinorTypeGTM or Marketing Partner
Description

ELMA appears in the collaborators section on Sincrolab's professional platform page. No further details available on the nature of the collaboration.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Laboratorios Rubio appears in the collaborators section. Sincrolab has announced intentions to develop partnerships with medical and pharmaceutical entities, which may include Laboratorios Rubio.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Sincrolab was accelerated by Telefónica, a major Spanish telecommunications and technology corporation. This affiliation provides potential go-to-market support, network access, and brand credibility within the Spanish tech ecosystem.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Developer of VR-based digital therapeutics for mental health and chronic pain conditions. Comparable as an emerging immersive-therapy DTx peer pursuing evidence-based, clinician-prescribed digital interventions, though using VR rather than mobile cognitive training.

TypeEmerging player
Description

AI-driven conversational mental health platform delivering CBT-informed chatbot interventions. Comparable in using AI to scale evidence-based mental health support and targeting the same clinician-payer ecosystem, though focused on conversational AI rather than adaptive cognitive training.

TypeBroad incumbent
Description

Broad digital mental health platform offering online ADHD evaluation, medication management, and therapy subscriptions in the U.S. Comparable as a scaled ADHD-focused digital mental health player, though operating with a telemedicine + prescribing model rather than a software-as-medical-device approach.

TypeBroad incumbent
Description

Digital therapeutics company behind Sleepio (insomnia) and Daylight (anxiety), delivering FDA-cleared and evidence-based cognitive behavioral therapies via mobile. Comparable as an established DTx competitor in mental health, though focused on sleep/anxiety rather than ADHD.

TypeEmerging player
Description

Developer of prescription digital therapeutics including treatments for IBS (Mahana IBS) and tinnitus. Comparable as an emerging DTx peer pursuing regulatory-cleared, evidence-based software therapies in adjacent chronic-condition categories.

TypeDirect peer
Description

Maker of EndeavorRx, the first FDA-cleared prescription video game-based digital therapeutic for pediatric ADHD. Directly comparable to Sincrolab in target indication (pediatric ADHD), delivery (mobile gamified cognitive therapy), regulatory pathway (cleared medical device), and GTM (clinician-prescribed, payor-reimbursed).

TypeDirect peer
Description

Developer of BrainHQ, a clinically validated cognitive training platform targeting attention, memory, and brain performance. Comparable in deploying gamified adaptive cognitive exercises with peer-reviewed efficacy data, though targeting a broader consumer and clinical audience than Sincrolab's ADHD-specific focus.

TypeDirect peer
Description

Prescription digital therapeutics company developing software-based treatments across mental health indications (depression, schizophrenia, migraine). Comparable as a DTx peer pursuing FDA-cleared, clinician-prescribed digital therapies in adjacent neuropsychiatric indications.

TypeDirect peer
Description

Provider of computerized cognitive assessment and training tools used in clinical trials and clinical practice. Comparable through its combination of validated cognitive testing (CPT-style measures) and clinician-facing cognitive health technology, overlapping with Sincrolab's evidence-based positioning.

TypeEmerging player
Description

AI-powered mental health platform supporting NHS psychological therapy services in the UK through patient-facing AI and clinician decision-support tools. Comparable in using AI to personalize mental-health interventions and reduce clinician burden, though operating in IAPT pathways rather than ADHD specifically.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sincrolab

Digital Therapeutics for ADHDsincrolab.es

Sincrolab is a Spanish digital therapeutics company that delivers CE-marked, AI-adaptive cognitive therapy for ADHD through its gamified 'Sea of Heroes' platform, sold via €99/month subscriptions to families and through professional licenses to clinicians, clinics, and hospitals across Spain.

What Sincrolab does

Sincrolab S.L. is a Spanish digital therapeutics company, founded in 2013 and headquartered in Madrid (with a registered office in Málaga), that develops AI-powered cognitive therapy software for ADHD and related cognitive disorders. Its core product, the KAD_SCL_01 cognitive stimulation program, deploys 14 adaptive cognitive tasks (including go/no-go and n-back paradigms) through the gamified 'Sea of Heroes' mobile application, with an AI engine that automatically adjusts task content and difficulty in real time based on each patient's daily performance. A separate professional platform allows therapists, clinics, and hospitals to prescribe treatment, monitor compliance, and generate automated progress reports, while families access the program through the Sincroclinic online booking and subscription flow.

Sincrolab holds CE Class IIa certification under EU Medical Device Regulation 2017/745 as the first Spanish company to secure this designation for an AI-based digital ADHD therapy, alongside ISO 13485:2016 (medical device quality) and ISO/IEC 27001:2022 (information security) certifications. Clinical validation rests on three peer-reviewed randomized controlled trials published in the Journal of Medical Internet Research (2021), Brain Communications (2022), and npj Mental Health Research/Nature (2025), with the most recent study reporting 28% of treated children reaching normative range on CPT-C versus 0% in controls and MEG-verified changes in brain activity.

The company monetizes through a €99/month B2C subscription sold directly to families via sincrolab.es, complemented by B2B subscriptions for healthcare professionals and partnerships with clinics, hospitals, and insurers (notably DKV), reaching a reported network of 800+ therapists and 100+ specialized centers across Spain with 6,000+ patients treated to date. Sincrolab has raised approximately €2 million cumulatively across rounds including Wayra (2015, 2018), a €1.7 million round led by Clave Innohealth in June 2024, and a 2026 Eoniq.fund follow-on at an €8.5 million pre-money valuation, with stated priorities of international expansion and new product launches in 2025.

Sincrolab firmographics

Firmographics
Name
Sincrolab
Legal name
SINCROLAB S.L.
Website
https://sincrolab.es
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
Sincrolab is a Spanish digital therapeutics company that delivers CE-marked, AI-adaptive cognitive therapy for ADHD through its gamified 'Sea of Heroes' platform, sold via €99/month subscriptions to families and through professional licenses to clinicians, clinics, and hospitals across Spain.
Ownership category
akta.pro rank

Sincrolab industry classification

Industry
Product category
Digital Therapeutics for ADHD
NAICS
Outpatient Mental Health and Substance Abuse Centers (621420)
SIC
Services-Prepackaged Software (7372), Services-Misc Health & Allied Services, Nec (8090)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLALAEAJ
Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching)
Healthcare & Life Sciences/Telehealth Platforms/Behavioral & Mental Health Teletherapy Platforms
SECONDARYHLALABAK
Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms
Healthcare & Life Sciences/Telehealth Platforms/Provider-Integrated Virtual Care Platforms (Health Systems/Clinics)

Keywords

  • Digital cognitive therapy
  • ADHD treatment platform
  • AI cognitive stimulation
  • Pediatric mental health
  • Gamified neurotherapy

Where Sincrolab is headquartered

Location

Headquarters

HQ city
Málaga
HQ country
Spain
HQ region
Europe

Offices2 records

Markets served

Sincrolab business model

Business model
GTM type
B2B and B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Suscripción Mensual Sincrolab (B2C): Monthly subscription model at €99/month for families, automatically renewed. Includes initial clinical assessment, personalized treatment plan, daily cognitive training activities via Sea of Heroes app, and ongoing professional supervision throughout the treatment cycle.
  2. B2B Platform Licensing / Professional Subscriptions: Sincrolab provides its professional platform to therapists, clinics, and hospitals who prescribe and monitor patient treatment. The platform allows professionals to customize treatment plans, supervise progress remotely, and generate automated reports for their patient base.
  3. Partnerships with Medical and Pharmaceutical Entities: Sincrolab is pursuing partnerships with medical and pharmaceutical entities as part of its expansion strategy, as stated in the Eoniq.fund investment announcement.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyMonthly subscription at €99 per month
One time/ perpetual licensePay-as-you-goInitial clinical assessment session (paid administrative fee)

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Sincrolab product offering

Product offering

Core offering

Sincrolab provides an AI-powered digital therapeutic platform for cognitive stimulation in children (and adults) with ADHD and attention difficulties. Its flagship product, the KAD_SCL_01 program, is delivered through the gamified 'Sea of Heroes' mobile app and comprises 14 adaptive cognitive tasks (go/no-go, n-back, etc.) that auto-adjust to patient performance, with online clinical assessment, monthly subscription pricing (€99/month), and ongoing professional supervision. A separate professional platform allows therapists, clinics, and hospitals to prescribe, monitor, and report on patient progress remotely.

Product overview

Sincrolab is a digital therapeutics company offering a unified platform combining AI-powered cognitive therapy (KAD_SCL_01) for ADHD and cognitive disorders. The core offering consists of the Sincrolab Platform for patients and professionals, the Sea of Heroes gamified therapy experience, and the Sincroclinic scheduling service. The platform is validated by clinical trials published in peer-reviewed journals including JMIR, Brain Communications, and Nature npj Mental Health Research, and holds CE Class IIa certification as a medical device for ADHD treatment. Pricing is via €99/month subscription through Sincroclinic.

Differentiator

Problem solved

Functional benefit

Brands

  • Sea of Heroes: A digital experience designed to accompany daily life with personalized activities, more motivation, and professional follow-up. A serious game with 14 cognitive tasks including go/no-go and n-back exercises that automatically adjust content and difficulty based on performance.

Products and services

  • Sincrolab Platform
  • Sea of Heroes
  • Sincrolab Therapist Platform
  • Sincroclinic
  • KAD_SCL_01 Cognitive Stimulation Program

Quantifiable outcome

  • 28% of the experimental group reached normative range on CPT-C (7/25 participants) vs 0% in control group (p=0.009), as demonstrated in the Nature npj Mental Health Research 2025 RCT
  • +5 more outcomes

Companies that use Sincrolab

Customer profile

Named customers6 records

Segments4 records

Ideal customer profiles3 records

Sincrolab technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Sincrolab partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered minor and core.

  • DKVminorGTM or Marketing PartnerDKV, a health insurance company, has a partnership or collaboration with Sincrolab. The DKV logo appears in the collaborators section on Sincrolab's professional platform page alongside Wayra, CTB, ELMA, Laboratorios Rubio, and IBM.
  • WayraminorGTM or Marketing PartnerWayra (Telefónica's tech venture capital / accelerator arm) appears in the collaborators section of Sincrolab's professional platform. The connection likely relates to Sincrolab's prior acceleration by Telefónica.
  • CTB (Centro de Tecnología Biomédica, UPM)coreStrategic or Co-development PartnerCTB (Centro de Tecnología Biomédica of Universidad Politécnica de Madrid) appears in the collaborators section. Fernando Maestú PhD, Director of the Cognitive Neuroscience and Computacional Lab at CTB, UPM, and UCM, serves on Sincrolab's Scientific Advisory Board, indicating a research collaboration.
  • ELMAminorGTM or Marketing PartnerELMA appears in the collaborators section on Sincrolab's professional platform page. No further details available on the nature of the collaboration.
  • Laboratorios RubiominorStrategic or Co-development PartnerLaboratorios Rubio appears in the collaborators section. Sincrolab has announced intentions to develop partnerships with medical and pharmaceutical entities, which may include Laboratorios Rubio.
  • TelefónicaminorGTM or Marketing PartnerSincrolab was accelerated by Telefónica, a major Spanish telecommunications and technology corporation. This affiliation provides potential go-to-market support, network access, and brand credibility within the Spanish tech ecosystem.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Sincrolab competitors and assessment

Company assessment

Emerging players

  • BehaVR: Developer of VR-based digital therapeutics for mental health and chronic pain conditions. Comparable as an emerging immersive-therapy DTx peer pursuing evidence-based, clinician-prescribed digital interventions, though using VR rather than mobile cognitive training.
  • Woebot Health: AI-driven conversational mental health platform delivering CBT-informed chatbot interventions. Comparable in using AI to scale evidence-based mental health support and targeting the same clinician-payer ecosystem, though focused on conversational AI rather than adaptive cognitive training.
  • Mahana Therapeutics: Developer of prescription digital therapeutics including treatments for IBS (Mahana IBS) and tinnitus. Comparable as an emerging DTx peer pursuing regulatory-cleared, evidence-based software therapies in adjacent chronic-condition categories.
  • Limbic: AI-powered mental health platform supporting NHS psychological therapy services in the UK through patient-facing AI and clinician decision-support tools. Comparable in using AI to personalize mental-health interventions and reduce clinician burden, though operating in IAPT pathways rather than ADHD specifically.

Broad incumbents

  • Cerebral: Broad digital mental health platform offering online ADHD evaluation, medication management, and therapy subscriptions in the U.S. Comparable as a scaled ADHD-focused digital mental health player, though operating with a telemedicine + prescribing model rather than a software-as-medical-device approach.
  • Big Health: Digital therapeutics company behind Sleepio (insomnia) and Daylight (anxiety), delivering FDA-cleared and evidence-based cognitive behavioral therapies via mobile. Comparable as an established DTx competitor in mental health, though focused on sleep/anxiety rather than ADHD.

Direct peers

  • Akili Interactive: Maker of EndeavorRx, the first FDA-cleared prescription video game-based digital therapeutic for pediatric ADHD. Directly comparable to Sincrolab in target indication (pediatric ADHD), delivery (mobile gamified cognitive therapy), regulatory pathway (cleared medical device), and GTM (clinician-prescribed, payor-reimbursed).
  • Posit Science: Developer of BrainHQ, a clinically validated cognitive training platform targeting attention, memory, and brain performance. Comparable in deploying gamified adaptive cognitive exercises with peer-reviewed efficacy data, though targeting a broader consumer and clinical audience than Sincrolab's ADHD-specific focus.
  • Click Therapeutics: Prescription digital therapeutics company developing software-based treatments across mental health indications (depression, schizophrenia, migraine). Comparable as a DTx peer pursuing FDA-cleared, clinician-prescribed digital therapies in adjacent neuropsychiatric indications.
  • Cogstate: Provider of computerized cognitive assessment and training tools used in clinical trials and clinical practice. Comparable through its combination of validated cognitive testing (CPT-style measures) and clinician-facing cognitive health technology, overlapping with Sincrolab's evidence-based positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

Sincrolab social profiles

Digital presence

Sincrolab compliance and trust

Trust signal

Compliance5 records

Sincrolab financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sincrolab leadership team

Management profile

Number of profiles

Profiles11 records

Sincrolab funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sincrolab M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sincrolab

What does Sincrolab do?

Sincrolab provides an AI-powered digital therapeutic platform for cognitive stimulation in children (and adults) with ADHD and attention difficulties. Its flagship product, the KAD_SCL_01 program, is delivered through the gamified 'Sea of Heroes' mobile app and comprises 14 adaptive cognitive tasks (go/no-go, n-back, etc.) that auto-adjust to patient performance, with online clinical assessment, monthly subscription pricing (€99/month), and ongoing professional supervision. A separate professional platform allows therapists, clinics, and hospitals to prescribe, monitor, and report on patient progress remotely.

Is Sincrolab a public or private company?

Sincrolab is a private company. It is classified as venture growth investor backed and is currently operating.

When was Sincrolab founded?

Sincrolab was founded in 2014. It employs 11 to 50 people.

Where is Sincrolab based?

Sincrolab is headquartered in Málaga, Spain, in the Europe region.

How does Sincrolab make money?

Three revenue lines are on record. Suscripción Mensual Sincrolab (B2C) is the primary driver. The others are B2B Platform Licensing / Professional Subscriptions and partnerships with Medical and Pharmaceutical Entities.

Who are Sincrolab's main competitors?

Emerging players on record are BehaVR, Woebot Health, Mahana Therapeutics and Limbic. Broad incumbents are Cerebral and Big Health. Direct peers are Akili Interactive, Posit Science, Click Therapeutics and Cogstate.

Does Sincrolab have an API?

No public API is recorded for Sincrolab.

What industry is Sincrolab in?

Sincrolab's product category is Digital Therapeutics for ADHD. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital), with a secondary code of HLALAEAJ, Neurodevelopmental & Behavioral Therapy Platforms (ADHD/Autism/Behavioral Coaching). Its NAICS code is 621420 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BusinessinsiderDe detectar cáncer a reducir la burocracia: la IA ya está cambiando el día a día en los hospitalesGoogle, Vall d'Hebron, and startups like Omniloy and Sincrolab are applying AI in hospitals for cancer screening, administrative tasks, and mental health. Google's AI reduces radiologist workload by 40% in breast cancer screening, while Omniloy pilots billing tools and Sincrolab develops digital mental health treatments. Experts call for better regulation and integration.WebcapitalriesgoEoniq.fund redobla su apuesta por Sincrolab (IA terapia cognitiva) con una inversión de €100.000Eoniq.fund has invested an additional €100,000 in Sincrolab, a digital health company specializing in AI-based cognitive therapy, bringing its total accumulated investment to €335,000 at a pre-money valuation of €8.5 million. Sincrolab has developed a platform that adapts treatments for children with ADHD and adults with cognitive impairment, currently serving over 800 therapists across more than 100 specialized centers and holding CE Class IIa certification for its digital ADHD solution. The funding will support technology development, market expansion, and partnerships with medical and pharmaceutical entities.Empresas de Capital Riesgo en EspaEoniq.fund strengthens its commitment to Sincrolab with a cumulative investment of €335,000 to advance AI-powered cognitive digital therapyEoniq.fund approved a €100,000 investment in Sincrolab, bringing its cumulative investment to €335,000. The funds will support AI engine enhancement, infrastructure scaling, and expansion into new markets. Sincrolab's AI-based cognitive therapy has shown efficacy in ADHD trials and holds CE Class IIa certification.El ReferenteSincrolab obtiene una inversión de 100.000 eurosSincrolab, a Spanish AI-based cognitive therapy platform, received a 100,000 euro investment from Eoniq.fund, bringing total funding to 335,000 euros. The funds will accelerate growth, product optimization, and clinical translation. The company's platform has been shown more effective than placebo in improving inhibitory control in ADHD patients.El ReferenteSincrolab obtiene una inversión de 100.000 eurosSincrolab, a Spanish AI-based cognitive therapy platform, received a 100,000 euro investment from Eoniq.fund, bringing total funding to 335,000 euros. The funds will accelerate growth, product optimization, and clinical translation. The company's platform has shown efficacy in controlled trials, with 54% of participants achieving significant improvements.El ReferenteSincrolab obtiene una inversión de 100.000 eurosSincrolab, a Spanish AI-based cognitive therapy platform, received a 100,000 euro investment from Eoniq.fund, bringing total funding to 335,000 euros. The funds will accelerate growth, product optimization, and clinical translation. The company's platform has been shown more effective than placebo in improving inhibitory control in ADHD patients.El ReferenteSincrolab obtiene una inversión de 100.000 eurosSincrolab, a Spanish AI-based cognitive therapy platform, received a 100,000-euro investment from Eoniq.fund, bringing total funding to 335,000 euros. The funds will accelerate growth, product optimization, and clinical translation. The company's platform has been shown more effective than placebo in improving inhibitory control in ADHD patients.WebcapitalriesgoClave Innohealth lidera una ronda de €1,7M en Sincrolab. Participan Growth VP, Eoniq y otrosClave Innohealth, a health-focused venture capital fund managed by Clave Capital, led a €1.7 million investment round in the Spanish healthtech startup Sincrolab. The funding will support Sincrolab's expansion into national and European markets and the development of new AI-based digital therapies for cognitive disorders scheduled for release in 2025. Co-investors Growth Venture Partners and Eoniq Fund also participated in this capital increase.